or Try an Advanced Search...

    Technical Analysis for CPRX - Catalyst Pharmaceutical Partners, Inc.

    Grade Last Price % Change Price Change
    D 15.05 -1.18% -0.18
    CPRX closed down 1.18 percent on Tuesday, April 30, 2024, on 89 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    Earnings due: May 8
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical CPRX trend table...
    Date Alert Name Type % Chg
    Bollinger Band Squeeze Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Gapped Down Weakness 0.00%
    Bollinger Band Squeeze Range Contraction -1.18%
    NR7 Range Contraction -1.18%
    NR7-2 Range Contraction -1.18%
    Oversold Stochastic Weakness -1.18%
    Stochastic Buy Signal Bullish 1.07%
    Older End-of-Day Signals for CPRX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 19 hours ago
    Down 2 % about 22 hours ago
    60 Minute Opening Range Breakdown about 22 hours ago
    Fell Below Previous Day's Low about 22 hours ago
    10 DMA Resistance about 23 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CPRX Chart by TradingView
    Basic chart:

    Profile

    Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. The company's principal product includes Firdapse that is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other selected central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Pharmaceutical Health Sciences Medication Virotherapy Disorders Epilepsy Pharmaceutical Sciences Prescription Drugs Stage Specialty Pharmaceutical Myasthenia Pharmaceutical Partners Treatment Of Epilepsy Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Tourette Syndrome Treatment Of Tourette Syndrome Urological Diseases

    Is CPRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 24 Dirt-Cheap Delights: 3 Discounted Stocks That Could Triple by 2026
    Apr 22 Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
    Apr 18 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is largely controlled by institutional shareholders who own 65% of the company
    Apr 13 Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024
    Apr 6 Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)
    Mar 29 Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
    Mar 28 Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
    Mar 27 Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
    Mar 27 3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
    Mar 22 Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen strong returns of 271% over the past three years
    See more CPRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.765
    52 Week Low 11.09
    Average Volume 1,372,435
    200-Day Moving Average 14.23
    50-Day Moving Average 15.54
    20-Day Moving Average 15.31
    10-Day Moving Average 15.13
    Average True Range 0.55
    RSI (14) 46.52
    ADX 16.0
    +DI 15.31
    -DI 20.14
    Chandelier Exit (Long, 3 ATRs) 14.59
    Chandelier Exit (Short, 3 ATRs) 16.25
    Upper Bollinger Bands 16.03
    Lower Bollinger Band 14.59
    Percent B (%b) 0.32
    BandWidth 9.37
    MACD Line -0.18
    MACD Signal Line -0.13
    MACD Histogram -0.0424
    Fundamentals Value
    Market Cap 1.79 Billion
    Num Shares 119 Million
    EPS 0.55
    Price-to-Earnings (P/E) Ratio 27.36
    Price-to-Sales 4.66
    Price-to-Book 4.66
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.44
    Resistance 3 (R3) 15.43 15.29 15.38
    Resistance 2 (R2) 15.29 15.19 15.30 15.35
    Resistance 1 (R1) 15.17 15.13 15.10 15.18 15.33
    Pivot Point 15.03 15.03 15.00 15.04 15.03
    Support 1 (S1) 14.91 14.93 14.84 14.92 14.77
    Support 2 (S2) 14.77 14.87 14.78 14.75
    Support 3 (S3) 14.65 14.77 14.73
    Support 4 (S4) 14.66